Compare Costco Wholesale Corporation (COST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Costco Wholesale Corporation trades at $943.13 (market cap $420.05B), while State Street SPDR S&P Biotech ETF trades at $154.09 (market cap $10.11B). The key difference: Costco Wholesale Corporation is far larger — about 41.5× State Street SPDR S&P Biotech ETF's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| COST | XBI | |
|---|---|---|
Market Cap | $420.05B | $10.11B |
Volume | 2,087,565 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $1.09K | $169.55 |
52-Week Low | $849.63 | $104.99 |
Typical Hold Time | 132 Days | 37 Days |
Enterprise Value | $407.33B | — |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $944.20, up 0.21% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong March 2026 sales growth of 11.3% year-over-year (Costco Wholesale Corporation, April 8, 2026) and has shown consistent revenue and net income growth, with fiscal 2025 revenue at $275.24B and net income at $8.10B. Analyst consensus is strongly bullish with a $1,100 price target, though valuation ratios like a P/E of 45.66 are elevated.
The outlook remains positive due to robust membership fee growth and expansion, but risks include high valuation sensitivity and competitive pressures. Upside is supported by strong institutional buying and earnings beats, though any market pullback could pressure the stock given its premium multiples.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
